Pdl Biopharma (PDLI) 8.60 $PDLI
PDL BioPharma Announces First Quarter 2014 Financial Results
PR Newswire - Mon May 12, 3:01PM CDT
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today reported financial results for the first quarter ended March 31, 2014.
Why DepoMed Inc. Shares Were Rocked
Sean Williams, The Motley Fool - Motley Fool - Fri May 09, 12:11PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of DepoMed , a specialty pharmaceutical...
PDL BioPharma to Present at the Bank of America Merrill Lynch 2014 Health Care Conference
PR Newswire - Thu May 08, 6:00AM CDT
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that Peter Garcia, the company's vice president and chief financial officer, will present at the Bank of America Merrill Lynch Health Care Conference next week in Las Vegas, Nevada. The presentation, which will be webcast, will occur on Thursday, May 15, 2014, at 12:40 p.m. PDT.
The 25 Top-Yielding Dividend Stocks in May
Dan Dzombak, The Motley Fool - Motley Fool - Wed May 07, 4:18PM CDT
Dividend investing is popular again. Investors have taken to heart Jeremy Siegel's studies, which show that higher-yielding stocks tend to offer greater returns over time than low- or no-yield stocks. The highest-paying dividend stocks can be very...
PDL BioPharma to Announce First Quarter 2014 Financial Results on May 12, 2014
PR Newswire - Wed May 07, 6:00AM CDT
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the Company will release its first quarter 2014 financial results for the period ended March 31, 2014, on Monday, May 12, 2014, after market close. PDL's management will host a conference call and webcast that day at 4:30 p.m. Eastern Time to discuss the financial results. A slide presentation relating to the call will be available via the webcast link on the PDL website.
Biotech Stocks Scanner -- Research on PDL BioPharma, Cytokinetics, Vical, and Peregrine Pharma
PR Newswire - Tue May 06, 11:41AM CDT
The markets on Monday, May 05, 2014 ended on a higher note as the S&P 500 finished the session 0.19% higher at 1,884.66, and the NASDAQ Composite closed at 4,138.06, up 0.34%. The Dow Jones Industrial Average finished at 16,530.55, up 0.11%. During the session, the eight out of ten sectors ended in positive. During the session gains in the Utilities, Health Care, and Materials sectors positively impacted the broader market, while some retraction came in from Consumer Staples and Financials sectors. The S&P 500 Health Care Sector Index closed the day at 672.57, up 0.56%, with the index also advancing 5.56% in the previous three months. Investor-Edge has initiated coverage on the following equities: PDL BioPharma Inc. (NASDAQ: PDLI), Cytokinetics Inc. (NASDAQ: CYTK), Vical Inc. (NASDAQ: VICL) and Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM). Free technical research on PDLI, CYTK, VICL and PPHM can be downloaded upon signing up at:
European Patent Office Names Inventors of PDL BioPharma's Antibody Technology as Finalists for European Inventor Award for 2014
PR Newswire - Tue May 06, 8:28AM CDT
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that two inventors of the company's patented breakthrough antibody technology have been named as a top-three finalist for the European Patent Office's highly prestigious 2014 European Inventor Award in the "Non-European Countries" category. The award, which is Europe's highest distinction for inventors, is presented annually by the European Patent Office, with support of the Presidency of the Council of the European Union and by the European Commission, to inventors who have made a significant contribution to innovation, economy and society in Europe and draws from all technological fields of endeavor.
2 Health Care Stocks to Watch: Enanta Pharmaceuticals, Inc. and PDLI BioPharma, Inc.
George Budwell, The Motley Fool - Motley Fool - Fri May 02, 5:24PM CDT
Bargain hunters have largely stayed away from health-care stocks over the last year and for good reason. Specifically, this group of stocks has generally soared to record high price-to-earnings ratios ever since 2012, making them some of the most...
Coverage of Biotech Equities -- Research on Arena Pharma, Celgene, PDL BioPharma, and Hemispherx Biopharma
PR Newswire - Tue Apr 08, 12:20PM CDT
On Monday, April 07, 2014, the NASDAQ Composite ended at 4,079.75, down 1.16%, the Dow Jones Industrial Average finished the session 1.02% lower at 16,245.87, and the S&P 500 closed at 1,845.04, down 1.08%. The losses were broad based as nine out of ten sectors finished on a lower note. The S&P 500 Health Care Sector Index finished the day 1.06% lower at 664.68, while the same has gained 3.19% in the previous three months. Investor-Edge has initiated coverage on the following equities: Arena Pharmaceuticals Inc. (NASDAQ: ARNA), Celgene Corp. (NASDAQ: CELG), PDL BioPharma Inc. (NASDAQ: PDLI) and Hemispherx Biopharma Inc. (NYSE MKT: HEB). Free technical research on ARNA, CELG, PDLI and HEB can be downloaded upon signing up at:
Kaleo awarded USD150m debt financing in support of EVZIO's commercial activities
M2 - Tue Apr 08, 7:07AM CDT
Pharmaceutical company Kaleo reported on Monday the execution of a USD150m debt facility with PDL BioPharma (NasdaqGS
DLI).
kaleo announces $150 million debt financing to support commercialization of EVZIO(TM)
PR Newswire - Mon Apr 07, 6:51AM CDT
Kaleo (formerly Intelliject) today announced that it has entered into a $150 million debt facility with PDL BioPharma (NASDAQ: PDLI) to enable kaleo to support commercialization of EVZIO(TM)(naloxone hydrochloride injection) and development of key pipeline products. Under the financing, PDL provided $150 million in cash at closing and will receive interest on the principal outstanding. The note is backed by royalty payments on kaleo's first product (Auvi-Q(TM) in the US and Allerject(TM) in Canada) (www.auvi-q.com) and a portion of the net sales on its second product (EVZIO(TM))(www.evzio.com). Once the note is repaid, kaleo will resume receiving 100% of all product royalties and net sales.
PDL BioPharma Completes $150 Million Financing Transaction with kaleo
PR Newswire - Mon Apr 07, 6:00AM CDT
PDL BioPharma, Inc. (NASDAQ: PDLI) today announced that it has acquired $150 million of Notes due 2029 (the Notes) from Accel 300, LLC, a wholly-owned subsidiary of kaleo, Inc. (formerly known as Intelliject, Inc.) (kaleo). The Notes are backed by 100 percent of royalties from kaleo's first approved product, Auvi-Q(TM) (epinephrine auto-injection, USP) (known as Allerject(TM) in Canada) and 10 percent of net sales of kaleo's second proprietary auto-injector based product, EVZIOTM (naloxone hydrochloride injection) (collectively, the Revenue Interests).
Business Plans, Clinical Trial Results, Meetings, Conferences, and Sponsorships - Analyst Notes on Baxter, Halozyme, WellCare, PDL BioPharma, and Lannett
PR Newswire - Tue Apr 01, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Baxter International Inc. (NYSE: BAX), Halozyme Therapeutics, Inc. (NASDAQ: HALO), WellCare Health Plans, Inc. (NYSE: WCG), PDL BioPharma, Inc. (NASDAQ: PDLI), and Lannett Company, Inc. (NYSE: LCI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Buy These Top 3 Buy-Rated Dividend Stocks Today: AB, PDLI, KIM
at The Street - Fri Mar 28, 10:30AM CDT
These 3 dividend stocks are rated a Buy by TheStreet
Depomed A 'Turtle' Gaining In Specialty Pharma Race
at Investor's Business Daily - Tue Mar 25, 4:52PM CDT
Specialty pharmaceutical company Depomed has been around nearly 20 years. But as CEO James Schoeneck says, it has only just begun to realize its potential. Of the four drugs in its product portfolio, three were acquired since 2012. The most recent,...
Momentum Indicators for Health Care Equities -- Research on Arena Pharma, Hemispherx Biopharma, PDL BioPharma and Celgene
PR Newswire - Thu Mar 20, 7:16AM CDT
The trading session on Wednesday, March 19, 2014 ended on a negative note as the S&P 500 finished at 1,860.77, down 0.61%; the NASDAQ Composite closed at 4,307.60, down 0.59%; the Dow Jones Industrial Average finished the session 0.70% lower at 16,222.17. The losses were broad based as all the sectors ended the session in negative. The S&P 500 Health Care Sector Index finished the day at 686.44, down 0.37%, while the same has advanced 1.72% in the previous three trading sessions. Investor-Edge has initiated coverage on the following equities: Arena Pharmaceuticals Inc. (NASDAQ: ARNA), Hemispherx Biopharma Inc. (AMEX: HEB), PDL BioPharma Inc. (NASDAQ: PDLI) and Celgene Corp. (NASDAQ: CELG). Free technical research on ARNA, HEB, PDLI and CELG can be downloaded upon signing up at:
5 Reasons to Buy PDL BioPharma Inc
George Budwell, The Motley Fool - Motley Fool - Mon Mar 17, 1:30PM CDT
The wisdom of investing in stocks that pay dividends will never go out of style. For investors in the health care sector, however, dividends are rare, as most health care companies choose to use their cash to invest in their clinical pipelines, which...
Deal Or No Deal: 4 Undervalued Dividend Stocks Under 10 Dollars
at The Street - Fri Mar 14, 4:02PM CDT
a����James Dennin, Kapitall: We built a list of undervalued dividend stocks that are also easy on the wallet. Is the market [...]
PDL BioPharma to Hold Annual Meeting of Stockholders on May 28, 2014
PR Newswire - Thu Mar 13, 3:02PM CDT
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the company will hold its annual meeting of stockholders on Wednesday, May 28, 2014, at 10:00 a.m. Pacific Time for all stockholders of record on April 4, 2014. The meeting will take place at the Hyatt Regency Hotel in Incline Village, Nevada.
Morning Movers in Biotech: Actavis plc, DepoMed, Inc. and Horizon Pharma, Inc.
George Budwell, The Motley Fool - Motley Fool - Thu Mar 13, 8:09AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at the top stories in biotech and health...
PDL BioPharma Announces First Quarter 2014 Financial Results
PR Newswire - Mon May 12, 3:01PM CDT
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today reported financial results for the first quarter ended March 31, 2014.
Why DepoMed Inc. Shares Were Rocked
Sean Williams, The Motley Fool - Motley Fool - Fri May 09, 12:11PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of DepoMed , a specialty pharmaceutical...
PDL BioPharma to Present at the Bank of America Merrill Lynch 2014 Health Care Conference
PR Newswire - Thu May 08, 6:00AM CDT
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that Peter Garcia, the company's vice president and chief financial officer, will present at the Bank of America Merrill Lynch Health Care Conference next week in Las Vegas, Nevada. The presentation, which will be webcast, will occur on Thursday, May 15, 2014, at 12:40 p.m. PDT.
The 25 Top-Yielding Dividend Stocks in May
Dan Dzombak, The Motley Fool - Motley Fool - Wed May 07, 4:18PM CDT
Dividend investing is popular again. Investors have taken to heart Jeremy Siegel's studies, which show that higher-yielding stocks tend to offer greater returns over time than low- or no-yield stocks. The highest-paying dividend stocks can be very...
PDL BioPharma to Announce First Quarter 2014 Financial Results on May 12, 2014
PR Newswire - Wed May 07, 6:00AM CDT
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the Company will release its first quarter 2014 financial results for the period ended March 31, 2014, on Monday, May 12, 2014, after market close. PDL's management will host a conference call and webcast that day at 4:30 p.m. Eastern Time to discuss the financial results. A slide presentation relating to the call will be available via the webcast link on the PDL website.
Biotech Stocks Scanner -- Research on PDL BioPharma, Cytokinetics, Vical, and Peregrine Pharma
PR Newswire - Tue May 06, 11:41AM CDT
The markets on Monday, May 05, 2014 ended on a higher note as the S&P 500 finished the session 0.19% higher at 1,884.66, and the NASDAQ Composite closed at 4,138.06, up 0.34%. The Dow Jones Industrial Average finished at 16,530.55, up 0.11%. During the session, the eight out of ten sectors ended in positive. During the session gains in the Utilities, Health Care, and Materials sectors positively impacted the broader market, while some retraction came in from Consumer Staples and Financials sectors. The S&P 500 Health Care Sector Index closed the day at 672.57, up 0.56%, with the index also advancing 5.56% in the previous three months. Investor-Edge has initiated coverage on the following equities: PDL BioPharma Inc. (NASDAQ: PDLI), Cytokinetics Inc. (NASDAQ: CYTK), Vical Inc. (NASDAQ: VICL) and Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM). Free technical research on PDLI, CYTK, VICL and PPHM can be downloaded upon signing up at:
European Patent Office Names Inventors of PDL BioPharma's Antibody Technology as Finalists for European Inventor Award for 2014
PR Newswire - Tue May 06, 8:28AM CDT
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that two inventors of the company's patented breakthrough antibody technology have been named as a top-three finalist for the European Patent Office's highly prestigious 2014 European Inventor Award in the "Non-European Countries" category. The award, which is Europe's highest distinction for inventors, is presented annually by the European Patent Office, with support of the Presidency of the Council of the European Union and by the European Commission, to inventors who have made a significant contribution to innovation, economy and society in Europe and draws from all technological fields of endeavor.
2 Health Care Stocks to Watch: Enanta Pharmaceuticals, Inc. and PDLI BioPharma, Inc.
George Budwell, The Motley Fool - Motley Fool - Fri May 02, 5:24PM CDT
Bargain hunters have largely stayed away from health-care stocks over the last year and for good reason. Specifically, this group of stocks has generally soared to record high price-to-earnings ratios ever since 2012, making them some of the most...
Coverage of Biotech Equities -- Research on Arena Pharma, Celgene, PDL BioPharma, and Hemispherx Biopharma
PR Newswire - Tue Apr 08, 12:20PM CDT
On Monday, April 07, 2014, the NASDAQ Composite ended at 4,079.75, down 1.16%, the Dow Jones Industrial Average finished the session 1.02% lower at 16,245.87, and the S&P 500 closed at 1,845.04, down 1.08%. The losses were broad based as nine out of ten sectors finished on a lower note. The S&P 500 Health Care Sector Index finished the day 1.06% lower at 664.68, while the same has gained 3.19% in the previous three months. Investor-Edge has initiated coverage on the following equities: Arena Pharmaceuticals Inc. (NASDAQ: ARNA), Celgene Corp. (NASDAQ: CELG), PDL BioPharma Inc. (NASDAQ: PDLI) and Hemispherx Biopharma Inc. (NYSE MKT: HEB). Free technical research on ARNA, CELG, PDLI and HEB can be downloaded upon signing up at:
Kaleo awarded USD150m debt financing in support of EVZIO's commercial activities
M2 - Tue Apr 08, 7:07AM CDT
Pharmaceutical company Kaleo reported on Monday the execution of a USD150m debt facility with PDL BioPharma (NasdaqGS
DLI). kaleo announces $150 million debt financing to support commercialization of EVZIO(TM)
PR Newswire - Mon Apr 07, 6:51AM CDT
Kaleo (formerly Intelliject) today announced that it has entered into a $150 million debt facility with PDL BioPharma (NASDAQ: PDLI) to enable kaleo to support commercialization of EVZIO(TM)(naloxone hydrochloride injection) and development of key pipeline products. Under the financing, PDL provided $150 million in cash at closing and will receive interest on the principal outstanding. The note is backed by royalty payments on kaleo's first product (Auvi-Q(TM) in the US and Allerject(TM) in Canada) (www.auvi-q.com) and a portion of the net sales on its second product (EVZIO(TM))(www.evzio.com). Once the note is repaid, kaleo will resume receiving 100% of all product royalties and net sales.
PDL BioPharma Completes $150 Million Financing Transaction with kaleo
PR Newswire - Mon Apr 07, 6:00AM CDT
PDL BioPharma, Inc. (NASDAQ: PDLI) today announced that it has acquired $150 million of Notes due 2029 (the Notes) from Accel 300, LLC, a wholly-owned subsidiary of kaleo, Inc. (formerly known as Intelliject, Inc.) (kaleo). The Notes are backed by 100 percent of royalties from kaleo's first approved product, Auvi-Q(TM) (epinephrine auto-injection, USP) (known as Allerject(TM) in Canada) and 10 percent of net sales of kaleo's second proprietary auto-injector based product, EVZIOTM (naloxone hydrochloride injection) (collectively, the Revenue Interests).
Business Plans, Clinical Trial Results, Meetings, Conferences, and Sponsorships - Analyst Notes on Baxter, Halozyme, WellCare, PDL BioPharma, and Lannett
PR Newswire - Tue Apr 01, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Baxter International Inc. (NYSE: BAX), Halozyme Therapeutics, Inc. (NASDAQ: HALO), WellCare Health Plans, Inc. (NYSE: WCG), PDL BioPharma, Inc. (NASDAQ: PDLI), and Lannett Company, Inc. (NYSE: LCI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Buy These Top 3 Buy-Rated Dividend Stocks Today: AB, PDLI, KIM
at The Street - Fri Mar 28, 10:30AM CDT
These 3 dividend stocks are rated a Buy by TheStreet
Depomed A 'Turtle' Gaining In Specialty Pharma Race
at Investor's Business Daily - Tue Mar 25, 4:52PM CDT
Specialty pharmaceutical company Depomed has been around nearly 20 years. But as CEO James Schoeneck says, it has only just begun to realize its potential. Of the four drugs in its product portfolio, three were acquired since 2012. The most recent,...
Momentum Indicators for Health Care Equities -- Research on Arena Pharma, Hemispherx Biopharma, PDL BioPharma and Celgene
PR Newswire - Thu Mar 20, 7:16AM CDT
The trading session on Wednesday, March 19, 2014 ended on a negative note as the S&P 500 finished at 1,860.77, down 0.61%; the NASDAQ Composite closed at 4,307.60, down 0.59%; the Dow Jones Industrial Average finished the session 0.70% lower at 16,222.17. The losses were broad based as all the sectors ended the session in negative. The S&P 500 Health Care Sector Index finished the day at 686.44, down 0.37%, while the same has advanced 1.72% in the previous three trading sessions. Investor-Edge has initiated coverage on the following equities: Arena Pharmaceuticals Inc. (NASDAQ: ARNA), Hemispherx Biopharma Inc. (AMEX: HEB), PDL BioPharma Inc. (NASDAQ: PDLI) and Celgene Corp. (NASDAQ: CELG). Free technical research on ARNA, HEB, PDLI and CELG can be downloaded upon signing up at:
5 Reasons to Buy PDL BioPharma Inc
George Budwell, The Motley Fool - Motley Fool - Mon Mar 17, 1:30PM CDT
The wisdom of investing in stocks that pay dividends will never go out of style. For investors in the health care sector, however, dividends are rare, as most health care companies choose to use their cash to invest in their clinical pipelines, which...
Deal Or No Deal: 4 Undervalued Dividend Stocks Under 10 Dollars
at The Street - Fri Mar 14, 4:02PM CDT
a����James Dennin, Kapitall: We built a list of undervalued dividend stocks that are also easy on the wallet. Is the market [...]
PDL BioPharma to Hold Annual Meeting of Stockholders on May 28, 2014
PR Newswire - Thu Mar 13, 3:02PM CDT
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the company will hold its annual meeting of stockholders on Wednesday, May 28, 2014, at 10:00 a.m. Pacific Time for all stockholders of record on April 4, 2014. The meeting will take place at the Hyatt Regency Hotel in Incline Village, Nevada.
Morning Movers in Biotech: Actavis plc, DepoMed, Inc. and Horizon Pharma, Inc.
George Budwell, The Motley Fool - Motley Fool - Thu Mar 13, 8:09AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at the top stories in biotech and health...
